Related Articles
Effect of the timing of discontinuation of last‑line chemotherapy on patient prognosis in advanced and recurrent gastric cancer
Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis
Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer
Safety and continuity of second‑ and third‑line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer